New obesity combo aims to preserve muscle while shedding fat
NCT ID NCT07671391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding LAE102 to the weight-loss drug tirzepatide can improve body composition in 60 adults with obesity. Participants receive weekly injections of either LAE102 plus tirzepatide or a placebo plus tirzepatide. The main goal is to see if the combination increases lean body mass after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LAE102 injection and tirzepatide
- What this could lead to
- If it works, this combination could help people with obesity lose fat while preserving or increasing muscle mass, improving overall body composition.
- What could go wrong
- This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The added benefit of LAE102 over tirzepatide alone is unproven, and side effects are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY ADULT ONSET are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.